CD4 and white blood cell declines caused by islatravir are dose-related and reversible, but rule out using it for prevention
Merck restarts islatravir HIV treatment studies, but abandons monthly PrEP
Vitamin D and calcium supplements suggested to avert bone disease in people taking tenofovir-based ART and PrEP
Injectable PrEP is just as effective for transgender women as it is for gay men, study analysis finds
New data suggest PrEP in pregnancy is safe
Nationwide Australian data shows PrEP has largely neutral effect on STI incidence
'Real-world' study finds PrEP may be stopping 60% of HIV infections in French men at high risk of HIV
Four in ten PrEP recipients stop taking it within six months, global meta-analysis reveals
Pregnant and breastfeeding cis women are paying the price for exclusion from PrEP research
